A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis
Phase of Trial: Phase I
Latest Information Update: 08 May 2015
Price : $35 *
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; Primary sclerosing cholangitis
- Focus Therapeutic Use
- 11 Sep 2013 Last checked against Mayo Clinic record.
- 11 Sep 2013 Planned End Date changed from 1 Dec 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov record.
- 11 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.